25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

VX1 (VERTEX PHARMACEUTIC (VX1.SG)) Stock Analysis
Buy, Hold or Sell?

Let's analyze VERTEX PHARMACEUTIC (VX1.SG) together

I guess you are interested in VERTEX PHARMACEUTIC (VX1.SG). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – VERTEX PHARMACEUTIC (VX1.SG)’s Financial Insights
  • 📈 Technical Analysis (TA) – VERTEX PHARMACEUTIC (VX1.SG)’s Price Targets

I'm going to help you getting a better view of VERTEX PHARMACEUTIC (VX1.SG). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about VERTEX PHARMACEUTIC (VX1.SG)

I send you an email if I find something interesting about VERTEX PHARMACEUTIC (VX1.SG).

1. Quick Overview

1.1. Quick analysis of VERTEX PHARMACEUTIC (VX1.SG) (30 sec.)










1.2. What can you expect buying and holding a share of VERTEX PHARMACEUTIC (VX1.SG)? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€56.87
Expected worth in 1 year
€52.99
How sure are you?
95.2%

+ What do you gain per year?

Total Gains per Share
€-3.88
Return On Investment
-1.0%

For what price can you sell your share?

Current Price per Share
€382.85
Expected price per share
€365.00 - €412.10
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of VERTEX PHARMACEUTIC (VX1.SG) (5 min.)




Live pricePrice per Share (EOD)
€382.85
Intrinsic Value Per Share
€-18.51 - €-25.47
Total Value Per Share
€38.35 - €31.39

2.2. Growth of VERTEX PHARMACEUTIC (VX1.SG) (5 min.)




Is VERTEX PHARMACEUTIC (VX1.SG) growing?

Current yearPrevious yearGrowGrow %
How rich?$16.4b$15.9b$341.4m2.1%

How much money is VERTEX PHARMACEUTIC (VX1.SG) making?

Current yearPrevious yearGrowGrow %
Making money-$133.8m$904.6m-$1b-775.8%
Net Profit Margin-6.5%36.6%--

How much money comes from the company's main activities?

2.3. Financial Health of VERTEX PHARMACEUTIC (VX1.SG) (5 min.)




2.4. Comparing to competitors in the Other industry (5 min.)




  Industry Rankings (Other)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of VERTEX PHARMACEUTIC (VX1.SG)?

Welcome investor! VERTEX PHARMACEUTIC (VX1.SG)'s management wants to use your money to grow the business. In return you get a share of VERTEX PHARMACEUTIC (VX1.SG).

First you should know what it really means to hold a share of VERTEX PHARMACEUTIC (VX1.SG). And how you can make/lose money.

Speculation

The Price per Share of VERTEX PHARMACEUTIC (VX1.SG) is €382.85. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of VERTEX PHARMACEUTIC (VX1.SG).
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in VERTEX PHARMACEUTIC (VX1.SG), you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €56.87. Based on the TTM, the Book Value Change Per Share is €-0.97 per quarter. Based on the YOY, the Book Value Change Per Share is €3.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of VERTEX PHARMACEUTIC (VX1.SG).

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps3.550.9%-0.52-0.1%3.510.9%2.080.5%2.220.6%1.950.5%
Usd Book Value Change Per Share3.220.8%-1.09-0.3%3.520.9%2.010.5%2.020.5%3.040.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share3.220.8%-1.09-0.3%3.520.9%2.010.5%2.020.5%3.040.8%
Usd Price Per Share437.05-458.92-369.60-376.14-315.24-271.91-
Price to Earnings Ratio30.76-19.06-26.62-22.94-30.42-26.37-
Price-to-Total Gains Ratio135.79-90.35-113.52-95.83-109.56-104.79-
Price to Book Ratio6.85-7.32-5.95-6.49-6.68-5.96-
Price-to-Total Gains Ratio135.79-90.35-113.52-95.83-109.56-104.79-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share429.86398
Number of shares2
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-1.092.02
Usd Total Gains Per Share-1.092.02
Gains per Quarter (2 shares)-2.184.04
Gains per Year (2 shares)-8.7116.14
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-9-190166
20-17-2803222
30-26-3704838
40-35-4606554
50-44-5508170
60-52-6409786
70-61-730113102
80-70-820129118
90-78-910145134
100-87-1000161150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%20.01.00.095.2%20.01.00.095.2%
Book Value Change Per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%20.01.00.095.2%20.01.00.095.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.021.00.0%0.00.021.00.0%
Total Gains per Share3.01.00.075.0%11.01.00.091.7%19.01.00.095.0%20.01.00.095.2%20.01.00.095.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of VERTEX PHARMACEUTIC (VX1.SG) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.866-0.970+134%3.136-9%1.794+60%1.797+59%2.708+6%
Book Value Per Share--56.86656.446+1%55.277+3%51.650+10%42.815+33%36.551+56%
Current Ratio--2.6922.795-4%4.123-35%3.939-32%4.033-33%3.968-32%
Debt To Asset Ratio--0.2720.265+3%0.236+15%0.244+11%0.250+9%0.256+6%
Debt To Equity Ratio--0.3730.362+3%0.310+21%0.324+15%0.335+11%0.344+8%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--94561590253.500100128804077.838-6%80428410616.613+18%81903783127.463+15%68704842257.490+38%67765135611.971+40%
Eps--3.164-0.459+115%3.126+1%1.851+71%1.982+60%1.735+82%
Ev To Sales Ratio--9.11810.232-11%9.1410%9.184-1%8.784+4%8.829+3%
Free Cash Flow Per Share--1.705-0.842+149%2.832-40%1.800-5%2.011-15%1.986-14%
Free Cash Flow To Equity Per Share--0.349-2.133+711%2.346-85%1.188-71%1.301-73%1.336-74%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---25.474----------
Intrinsic Value_10Y_min---18.514----------
Intrinsic Value_1Y_max--5.795----------
Intrinsic Value_1Y_min--5.697----------
Intrinsic Value_3Y_max--11.050----------
Intrinsic Value_3Y_min--10.678----------
Intrinsic Value_5Y_max--8.635----------
Intrinsic Value_5Y_min--8.562----------
Market Cap--100014043693.500105351244937.838-5%84832351276.613+18%86219106727.463+16%72359954603.130+38%62423273114.275+60%
Net Profit Margin--0.314-0.065+121%0.366-14%0.224+40%0.283+11%0.280+12%
Operating Margin----0%-0%-0%0.106-100%0.148-100%
Operating Ratio--0.7630.740+3%0.743+3%0.705+8%0.706+8%0.730+5%
Pb Ratio6.733-2%6.8457.320-6%5.950+15%6.488+6%6.681+2%5.959+15%
Pe Ratio30.251-2%30.75719.058+61%26.616+16%22.937+34%30.420+1%26.372+17%
Price Per Share382.850-2%389.250408.725-5%329.175+18%335.004+16%280.766+39%242.170+61%
Price To Free Cash Flow Ratio56.137-2%57.07624.606+132%73.022-22%39.115+46%27.764+106%24.526+133%
Price To Total Gains Ratio133.562-2%135.79490.349+50%113.523+20%95.831+42%109.558+24%104.789+30%
Quick Ratio--0.8850.800+11%0.751+18%0.791+12%0.816+9%0.828+7%
Return On Assets--0.041-0.011+128%0.043-6%0.028+46%0.039+4%0.039+4%
Return On Equity--0.056-0.015+128%0.056-1%0.036+55%0.052+8%0.052+7%
Total Gains Per Share--2.866-0.970+134%3.136-9%1.794+60%1.797+59%2.708+6%
Usd Book Value--16405351882.75216336219784.304+0%15994783198.296+3%14924493679.928+10%12384235238.989+32%11200464589.557+46%
Usd Book Value Change Per Share--3.218-1.089+134%3.521-9%2.014+60%2.018+59%3.040+6%
Usd Book Value Per Share--63.84963.378+1%62.065+3%57.992+10%48.073+33%41.039+56%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--106173753536.630112424621218.596-6%90305019440.333+18%91961567695.515+15%77141796886.709+38%76086694265.121+40%
Usd Eps--3.552-0.515+115%3.510+1%2.078+71%2.225+60%1.948+82%
Usd Free Cash Flow--491872631.040-244436703.840+150%819512789.592-40%518707348.936-5%581264833.194-15%546616205.354-10%
Usd Free Cash Flow Per Share--1.914-0.945+149%3.180-40%2.021-5%2.258-15%2.230-14%
Usd Free Cash Flow To Equity Per Share--0.392-2.395+711%2.634-85%1.334-71%1.461-73%1.500-74%
Usd Market Cap--112295768259.062118288377816.204-5%95249764013.381+18%96806813033.595+16%81245757028.394+38%70088851052.708+60%
Usd Price Per Share429.864-2%437.050458.916-5%369.598+18%376.143+16%315.244+39%271.908+61%
Usd Profit--912763642.560-133865335.968+115%904665739.488+1%533695134.560+71%572839015.035+59%526386902.005+73%
Usd Revenue--2911246141.4402754311779.128+6%2466661265.376+18%2484356683.200+17%2179439790.526+34%1989605797.476+46%
Usd Total Gains Per Share--3.218-1.089+134%3.521-9%2.014+60%2.018+59%3.040+6%
 EOD+4 -2MRQTTM+23 -12YOY+15 -203Y+21 -145Y+22 -1410Y+22 -14

3.3 Fundamental Score

Let's check the fundamental score of VERTEX PHARMACEUTIC (VX1.SG) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1530.251
Price to Book Ratio (EOD)Between0-16.733
Net Profit Margin (MRQ)Greater than00.314
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.885
Current Ratio (MRQ)Greater than12.692
Debt to Asset Ratio (MRQ)Less than10.272
Debt to Equity Ratio (MRQ)Less than10.373
Return on Equity (MRQ)Greater than0.150.056
Return on Assets (MRQ)Greater than0.050.041
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of VERTEX PHARMACEUTIC (VX1.SG) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5027.317
Ma 20Greater thanMa 50429.545
Ma 50Greater thanMa 100445.827
Ma 100Greater thanMa 200435.286
OpenGreater thanClose383.350
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About VERTEX PHARMACEUTIC (VX1.SG)

  • Other
  • 0

There is no Profile data available for VX1.SG.

Fundamental data was last updated by Penke on 2025-04-25 13:37:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is underpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit VERTEX PHARMACEUTIC (VX1.SG) earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare VERTEX PHARMACEUTIC (VX1.SG) to the Other industry mean.
  • A Net Profit Margin of 31.4% means that €0.31 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of VERTEX PHARMACEUTIC (VX1.SG):

  • The MRQ is 31.4%. The company is making a huge profit. +2
  • The TTM is -6.5%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ31.4%TTM-6.5%+37.8%
TTM-6.5%YOY36.6%-43.1%
TTM-6.5%5Y28.3%-34.8%
5Y28.3%10Y28.0%+0.3%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ31.4%6.6%+24.8%
TTM-6.5%5.9%-12.4%
YOY36.6%5.7%+30.9%
3Y22.4%5.7%+16.7%
5Y28.3%6.1%+22.2%
10Y28.0%6.5%+21.5%
4.3.1.2. Return on Assets

Shows how efficient VERTEX PHARMACEUTIC (VX1.SG) is using its assets to generate profit.

  • Above 5% is considered healthy but always compare VERTEX PHARMACEUTIC (VX1.SG) to the Other industry mean.
  • 4.1% Return on Assets means that VERTEX PHARMACEUTIC (VX1.SG) generated €0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of VERTEX PHARMACEUTIC (VX1.SG):

  • The MRQ is 4.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is -1.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ4.1%TTM-1.1%+5.2%
TTM-1.1%YOY4.3%-5.4%
TTM-1.1%5Y3.9%-5.0%
5Y3.9%10Y3.9%0.0%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ4.1%1.2%+2.9%
TTM-1.1%1.0%-2.1%
YOY4.3%0.9%+3.4%
3Y2.8%1.0%+1.8%
5Y3.9%1.0%+2.9%
10Y3.9%1.1%+2.8%
4.3.1.3. Return on Equity

Shows how efficient VERTEX PHARMACEUTIC (VX1.SG) is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare VERTEX PHARMACEUTIC (VX1.SG) to the Other industry mean.
  • 5.6% Return on Equity means VERTEX PHARMACEUTIC (VX1.SG) generated €0.06 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of VERTEX PHARMACEUTIC (VX1.SG):

  • The MRQ is 5.6%. Using its investors money, the company is less efficient in making profit.
  • The TTM is -1.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ5.6%TTM-1.5%+7.1%
TTM-1.5%YOY5.6%-7.2%
TTM-1.5%5Y5.2%-6.7%
5Y5.2%10Y5.2%0.0%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ5.6%3.0%+2.6%
TTM-1.5%2.5%-4.0%
YOY5.6%3.0%+2.6%
3Y3.6%3.3%+0.3%
5Y5.2%3.1%+2.1%
10Y5.2%3.1%+2.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of VERTEX PHARMACEUTIC (VX1.SG).

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient VERTEX PHARMACEUTIC (VX1.SG) is operating .

  • Measures how much profit VERTEX PHARMACEUTIC (VX1.SG) makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare VERTEX PHARMACEUTIC (VX1.SG) to the Other industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of VERTEX PHARMACEUTIC (VX1.SG):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y10.6%-10.6%
5Y10.6%10Y14.8%-4.2%
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.4%-12.4%
TTM-8.0%-8.0%
YOY-7.4%-7.4%
3Y-3.9%-3.9%
5Y10.6%3.3%+7.3%
10Y14.8%6.1%+8.7%
4.3.2.2. Operating Ratio

Measures how efficient VERTEX PHARMACEUTIC (VX1.SG) is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Other industry mean).
  • An Operation Ratio of 0.76 means that the operating costs are €0.76 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of VERTEX PHARMACEUTIC (VX1.SG):

  • The MRQ is 0.763. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.740. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.763TTM0.740+0.024
TTM0.740YOY0.743-0.003
TTM0.7405Y0.706+0.034
5Y0.70610Y0.730-0.025
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7631.533-0.770
TTM0.7401.509-0.769
YOY0.7431.515-0.772
3Y0.7051.553-0.848
5Y0.7061.513-0.807
10Y0.7301.509-0.779
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of VERTEX PHARMACEUTIC (VX1.SG).

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if VERTEX PHARMACEUTIC (VX1.SG) is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Other industry mean).
  • A Current Ratio of 2.69 means the company has €2.69 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of VERTEX PHARMACEUTIC (VX1.SG):

  • The MRQ is 2.692. The company is able to pay all its short-term debts. +1
  • The TTM is 2.795. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.692TTM2.795-0.103
TTM2.795YOY4.123-1.328
TTM2.7955Y4.033-1.238
5Y4.03310Y3.968+0.065
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6921.408+1.284
TTM2.7951.344+1.451
YOY4.1231.538+2.585
3Y3.9391.481+2.458
5Y4.0331.496+2.537
10Y3.9681.464+2.504
4.4.3.2. Quick Ratio

Measures if VERTEX PHARMACEUTIC (VX1.SG) is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare VERTEX PHARMACEUTIC (VX1.SG) to the Other industry mean.
  • A Quick Ratio of 0.89 means the company can pay off €0.89 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of VERTEX PHARMACEUTIC (VX1.SG):

  • The MRQ is 0.885. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.800. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.885TTM0.800+0.086
TTM0.800YOY0.751+0.048
TTM0.8005Y0.816-0.016
5Y0.81610Y0.828-0.012
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8850.452+0.433
TTM0.8000.487+0.313
YOY0.7510.516+0.235
3Y0.7910.522+0.269
5Y0.8160.548+0.268
10Y0.8280.551+0.277
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of VERTEX PHARMACEUTIC (VX1.SG).

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of VERTEX PHARMACEUTIC (VX1.SG) assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare VERTEX PHARMACEUTIC (VX1.SG) to Other industry mean.
  • A Debt to Asset Ratio of 0.27 means that VERTEX PHARMACEUTIC (VX1.SG) assets are financed with 27.2% credit (debt) and the remaining percentage (100% - 27.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of VERTEX PHARMACEUTIC (VX1.SG):

  • The MRQ is 0.272. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.265. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.272TTM0.265+0.007
TTM0.265YOY0.236+0.028
TTM0.2655Y0.250+0.015
5Y0.25010Y0.256-0.005
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2720.551-0.279
TTM0.2650.563-0.298
YOY0.2360.548-0.312
3Y0.2440.545-0.301
5Y0.2500.572-0.322
10Y0.2560.579-0.323
4.5.4.2. Debt to Equity Ratio

Measures if VERTEX PHARMACEUTIC (VX1.SG) is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare VERTEX PHARMACEUTIC (VX1.SG) to the Other industry mean.
  • A Debt to Equity ratio of 37.3% means that company has €0.37 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of VERTEX PHARMACEUTIC (VX1.SG):

  • The MRQ is 0.373. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.362. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.373TTM0.362+0.011
TTM0.362YOY0.310+0.052
TTM0.3625Y0.335+0.027
5Y0.33510Y0.344-0.010
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3731.266-0.893
TTM0.3621.345-0.983
YOY0.3101.380-1.070
3Y0.3241.534-1.210
5Y0.3351.489-1.154
10Y0.3441.592-1.248
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings VERTEX PHARMACEUTIC (VX1.SG) generates.

  • Above 15 is considered overpriced but always compare VERTEX PHARMACEUTIC (VX1.SG) to the Other industry mean.
  • A PE ratio of 30.76 means the investor is paying €30.76 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of VERTEX PHARMACEUTIC (VX1.SG):

  • The EOD is 30.251. Based on the earnings, the company is overpriced. -1
  • The MRQ is 30.757. Based on the earnings, the company is overpriced. -1
  • The TTM is 19.058. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD30.251MRQ30.757-0.506
MRQ30.757TTM19.058+11.699
TTM19.058YOY26.616-7.557
TTM19.0585Y30.420-11.362
5Y30.42010Y26.372+4.048
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD30.25111.532+18.719
MRQ30.75711.147+19.610
TTM19.05812.134+6.924
YOY26.61610.701+15.915
3Y22.9379.625+13.312
5Y30.42011.516+18.904
10Y26.37211.042+15.330
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of VERTEX PHARMACEUTIC (VX1.SG):

  • The EOD is 56.137. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 57.076. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 24.606. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD56.137MRQ57.076-0.938
MRQ57.076TTM24.606+32.470
TTM24.606YOY73.022-48.417
TTM24.6065Y27.764-3.159
5Y27.76410Y24.526+3.238
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD56.1378.845+47.292
MRQ57.0768.068+49.008
TTM24.6068.098+16.508
YOY73.0222.110+70.912
3Y39.1151.876+37.239
5Y27.7644.048+23.716
10Y24.5261.825+22.701
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of VERTEX PHARMACEUTIC (VX1.SG) is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Other industry mean).
  • A PB ratio of 6.85 means the investor is paying €6.85 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of VERTEX PHARMACEUTIC (VX1.SG):

  • The EOD is 6.733. Based on the equity, the company is overpriced. -1
  • The MRQ is 6.845. Based on the equity, the company is overpriced. -1
  • The TTM is 7.320. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.733MRQ6.845-0.113
MRQ6.845TTM7.320-0.475
TTM7.320YOY5.950+1.371
TTM7.3205Y6.681+0.640
5Y6.68110Y5.959+0.722
Compared to industry (Other)
PeriodCompanyIndustry (mean)+/- 
EOD6.7331.233+5.500
MRQ6.8451.244+5.601
TTM7.3201.353+5.967
YOY5.9501.308+4.642
3Y6.4881.351+5.137
5Y6.6811.682+4.999
10Y5.9591.636+4.323
4.6.2. Total Gains per Share

2.4. Latest News of VERTEX PHARMACEUTIC (VX1.SG)

Does VERTEX PHARMACEUTIC (VX1.SG) still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from VERTEX PHARMACEUTIC (VX1.SG) to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-04-14
19:37
April 2025's Stocks That May Be Priced Below Their Estimated ValueRead
2025-04-10
23:50
Vertex Pharmaceuticals (VRTX) Stock Moves -1.41%: What You Should KnowRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets22,533,200
Total Liabilities6,123,600
Total Stockholder Equity16,409,600
 As reported
Total Liabilities 6,123,600
Total Stockholder Equity+ 16,409,600
Total Assets = 22,533,200

Assets

Total Assets22,533,200
Total Current Assets9,596,400
Long-term Assets12,936,800
Total Current Assets
Cash And Cash Equivalents 4,569,600
Short-term Investments 1,546,300
Net Receivables 1,609,400
Inventory 1,205,400
Other Current Assets 76,400
Total Current Assets  (as reported)9,596,400
Total Current Assets  (calculated)9,007,100
+/- 589,300
Long-term Assets
Property Plant Equipment 2,584,600
Goodwill 1,088,000
Long Term Investments 5,107,900
Intangible Assets 825,900
Long-term Assets Other 999,300
Long-term Assets  (as reported)12,936,800
Long-term Assets  (calculated)10,605,700
+/- 2,331,100

Liabilities & Shareholders' Equity

Total Current Liabilities3,564,600
Long-term Liabilities2,559,000
Total Stockholder Equity16,409,600
Total Current Liabilities
Accounts payable 413,000
Other Current Liabilities 31,400
Total Current Liabilities  (as reported)3,564,600
Total Current Liabilities  (calculated)444,400
+/- 3,120,200
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,749,500
Long-term Liabilities Other 203,200
Long-term Liabilities  (as reported)2,559,000
Long-term Liabilities  (calculated)1,952,700
+/- 606,300
Total Stockholder Equity
Retained Earnings 9,606,800
Total Stockholder Equity (as reported)16,409,600
Total Stockholder Equity (calculated)9,606,800
+/- 6,802,800
Other
Capital Stock2,600
Common Stock Shares Outstanding 256,940
Net Invested Capital 16,409,600
Net Working Capital 6,031,800
Property Plant and Equipment Gross 3,649,400



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
6,543,114
7,033,471
7,514,553
8,318,465
8,893,201
10,216,367
11,301,633
11,751,808
12,115,059
12,221,686
12,618,745
13,432,500
14,256,100
15,582,200
16,706,400
18,150,900
18,974,200
20,349,200
21,726,200
22,730,200
23,917,400
20,132,100
22,240,200
22,533,200
22,533,20022,240,20020,132,10023,917,40022,730,20021,726,20020,349,20018,974,20018,150,90016,706,40015,582,20014,256,10013,432,50012,618,74512,221,68612,115,05911,751,80811,301,63310,216,3678,893,2018,318,4657,514,5537,033,4716,543,114
   > Total Current Assets 
4,183,039
4,710,968
4,777,094
4,822,829
5,446,400
6,694,320
7,458,456
8,133,379
8,539,307
8,457,514
8,852,540
9,560,600
9,869,800
10,954,000
11,544,100
13,234,800
12,965,700
13,872,900
14,695,800
14,144,200
13,288,700
8,941,600
9,804,100
9,596,400
9,596,4009,804,1008,941,60013,288,70014,144,20014,695,80013,872,90012,965,70013,234,80011,544,10010,954,0009,869,8009,560,6008,852,5408,457,5148,539,3078,133,3797,458,4566,694,3205,446,4004,822,8294,777,0944,710,9684,183,039
       Cash And Cash Equivalents 
2,893,885
3,294,684
3,397,941
3,109,322
3,593,412
4,831,332
5,358,087
5,988,187
6,304,330
6,063,678
6,275,698
6,795,000
7,600,100
8,702,200
9,171,500
10,504,000
9,289,900
10,151,100
11,110,200
10,369,100
9,158,000
4,580,100
5,239,200
4,569,600
4,569,6005,239,2004,580,1009,158,00010,369,10011,110,20010,151,1009,289,90010,504,0009,171,5008,702,2007,600,1006,795,0006,275,6986,063,6786,304,3305,988,1875,358,0874,831,3323,593,4123,109,3223,397,9413,294,6842,893,885
       Short-term Investments 
584,150
656,538
598,390
698,972
596,984
619,437
792,971
670,710
619,638
644,315
685,187
729,900
638,000
551,200
599,200
274,500
1,124,200
1,085,200
818,000
849,200
1,013,300
1,215,400
1,285,300
1,546,300
1,546,3001,285,3001,215,4001,013,300849,200818,0001,085,2001,124,200274,500599,200551,200638,000729,900685,187644,315619,638670,710792,971619,437596,984698,972598,390656,538584,150
       Net Receivables 
438,297
464,900
443,315
633,518
845,269
791,768
791,917
885,352
977,551
929,142
1,100,372
1,136,800
1,292,800
1,332,900
1,385,200
1,442,200
1,547,800
1,556,200
1,538,700
1,563,400
1,793,200
1,656,100
1,750,600
1,609,400
1,609,4001,750,6001,656,1001,793,2001,563,4001,538,7001,556,2001,547,8001,442,2001,385,2001,332,9001,292,8001,136,8001,100,372929,142977,551885,352791,917791,768845,269633,518443,315464,900438,297
       Inventory 
136,698
143,017
162,306
167,502
187,087
219,218
245,460
280,777
298,863
321,620
333,456
353,100
338,900
367,700
388,200
460,600
535,100
603,500
688,700
738,800
813,100
914,600
1,079,800
1,205,400
1,205,4001,079,800914,600813,100738,800688,700603,500535,100460,600388,200367,700338,900353,100333,456321,620298,863280,777245,460219,218187,087167,502162,306143,017136,698
   > Long-term Assets 
2,360,075
2,322,503
2,737,459
3,495,636
3,446,801
3,522,047
3,843,177
3,618,429
3,575,752
3,764,172
3,766,205
3,871,900
4,386,300
4,628,200
5,162,300
4,916,100
6,008,500
6,476,300
7,030,400
8,586,000
10,628,700
11,190,500
12,436,100
12,936,800
12,936,80012,436,10011,190,50010,628,7008,586,0007,030,4006,476,3006,008,5004,916,1005,162,3004,628,2004,386,3003,871,9003,766,2053,764,1723,575,7523,618,4293,843,1773,522,0473,446,8013,495,6362,737,4592,322,5032,360,075
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,118,700
1,455,800
1,448,000
1,446,700
1,434,500
1,452,900
1,485,700
1,770,700
2,513,900
2,584,600
2,584,6002,513,9001,770,7001,485,7001,452,9001,434,5001,446,7001,448,0001,455,8001,118,70000000000000000
       Goodwill 
50,384
50,384
447,525
1,002,158
1,002,158
1,002,158
1,002,158
1,002,158
1,002,158
1,002,158
1,002,158
1,002,200
1,402,200
1,389,200
1,075,200
1,088,000
1,088,000
1,088,000
1,088,000
1,088,000
1,088,000
1,088,000
1,088,000
1,088,000
1,088,0001,088,0001,088,0001,088,0001,088,0001,088,0001,088,0001,088,0001,088,0001,075,2001,389,2001,402,2001,002,2001,002,1581,002,1581,002,1581,002,1581,002,1581,002,1581,002,1581,002,158447,52550,38450,384
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
112,200
1,081,500
1,357,300
1,700,000
2,497,800
4,381,400
4,393,100
4,703,500
5,107,900
5,107,9004,703,5004,393,1004,381,4002,497,8001,700,0001,357,3001,081,500112,200000000000000000
       Intangible Assets 
0
0
0
400,000
400,000
400,000
400,000
400,000
400,000
400,000
400,000
400,000
400,000
387,000
603,600
603,600
603,600
603,600
603,600
839,900
834,900
837,500
831,600
825,900
825,900831,600837,500834,900839,900603,600603,600603,600603,600603,600387,000400,000400,000400,000400,000400,000400,000400,000400,000400,000400,000000
       Long-term Assets Other 
39,041
57,766
79,985
157,583
160,635
176,564
372,290
49,394
49,262
71,099
75,518
110,800
931,200
995,100
1,202,100
409,600
427,500
442,700
475,200
895,300
875,700
915,600
990,200
999,300
999,300990,200915,600875,700895,300475,200442,700427,500409,6001,202,100995,100931,200110,80075,51871,09949,26249,394372,290176,564160,635157,58379,98557,76639,041
> Total Liabilities 
1,819,801
1,963,506
2,261,159
2,233,221
2,431,547
2,697,125
3,168,160
3,064,993
3,134,805
3,025,290
3,088,037
3,332,500
3,349,100
3,648,700
3,676,800
4,238,200
4,541,900
4,879,000
5,213,400
5,149,800
5,370,800
5,357,400
6,609,300
6,123,600
6,123,6006,609,3005,357,4005,370,8005,149,8005,213,4004,879,0004,541,9004,238,2003,676,8003,648,7003,349,1003,332,5003,088,0373,025,2903,134,8053,064,9933,168,1602,697,1252,431,5472,233,2212,261,1591,963,5061,819,801
   > Total Current Liabilities 
1,106,468
1,259,220
1,388,894
1,334,827
1,538,750
1,798,640
2,004,026
1,877,533
1,944,050
1,836,448
1,914,264
2,142,000
1,894,100
2,317,500
2,391,300
2,742,100
3,026,200
3,352,100
3,599,400
3,547,400
3,795,900
3,547,200
3,973,100
3,564,600
3,564,6003,973,1003,547,2003,795,9003,547,4003,599,4003,352,1003,026,2002,742,1002,391,3002,317,5001,894,1002,142,0001,914,2641,836,4481,944,0501,877,5332,004,0261,798,6401,538,7501,334,8271,388,8941,259,2201,106,468
       Accounts payable 
82,262
77,045
92,528
87,610
100,703
101,451
107,786
155,139
127,839
127,534
127,863
195,000
173,600
198,000
126,900
303,900
323,200
363,000
375,900
364,900
351,400
327,900
395,800
413,000
413,000395,800327,900351,400364,900375,900363,000323,200303,900126,900198,000173,600195,000127,863127,534127,839155,139107,786101,451100,70387,61092,52877,04582,262
       Other Current Liabilities 
108,758
113,103
122,583
130,305
179,776
151,782
192,541
83,470
284,174
226,358
201,409
49,800
286,100
238,700
218,000
62,500
377,000
391,000
316,200
273,200
648,600
279,300
357,600
31,400
31,400357,600279,300648,600273,200316,200391,000377,00062,500218,000238,700286,10049,800201,409226,358284,17483,470192,541151,782179,776130,305122,583113,103108,758
   > Long-term Liabilities 
713,333
704,286
872,265
898,394
892,797
898,485
1,164,134
1,187,460
1,190,755
1,188,842
1,173,773
1,190,500
1,455,000
1,331,200
1,285,500
1,496,100
1,515,700
1,526,900
1,614,000
1,602,400
1,574,900
1,810,200
2,636,200
2,559,000
2,559,0002,636,2001,810,2001,574,9001,602,4001,614,0001,526,9001,515,7001,496,1001,285,5001,331,2001,455,0001,190,5001,173,7731,188,8421,190,7551,187,4601,164,134898,485892,797898,394872,265704,286713,333
       Capital Lease Obligations Min Short Term Debt
623,865
611,963
604,539
538,576
532,952
522,067
546,514
931,939
898,797
893,849
876,800
934,100
544,200
531,600
482,000
899,700
789,200
767,600
744,700
808,400
721,300
933,400
1,702,900
1,749,500
1,749,5001,702,900933,400721,300808,400744,700767,600789,200899,700482,000531,600544,200934,100876,800893,849898,797931,939546,514522,067532,952538,576604,539611,963623,865
       Long-term Liabilities Other 
5,997
8,014
182,642
359,818
359,845
376,418
617,620
297,955
291,958
294,993
296,973
303,300
910,800
799,600
803,500
233,000
726,500
759,300
869,300
196,300
853,600
876,800
933,300
203,200
203,200933,300876,800853,600196,300869,300759,300726,500233,000803,500799,600910,800303,300296,973294,993291,958297,955617,620376,418359,845359,818182,6428,0145,997
> Total Stockholder Equity
4,723,313
5,069,965
5,253,394
6,085,244
6,461,654
7,519,242
8,133,473
8,686,815
8,980,254
9,196,396
9,530,708
10,100,000
10,907,000
11,933,500
13,029,600
13,912,700
14,432,300
15,470,200
16,512,800
17,580,400
18,546,600
14,774,700
15,630,900
16,409,600
16,409,60015,630,90014,774,70018,546,60017,580,40016,512,80015,470,20014,432,30013,912,70013,029,60011,933,50010,907,00010,100,0009,530,7089,196,3968,980,2548,686,8158,133,4737,519,2426,461,6546,085,2445,253,3945,069,9654,723,313
   Common Stock000000000000000000000000
   Retained Earnings Total Equity000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000
   Capital Surplus 000000000000000000000000
   Treasury Stock000000000000000000000000
   Other Stockholders Equity 000000000000000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue11,020,100
Cost of Revenue-1,530,500
Gross Profit9,489,6009,489,600
 
Operating Income (+$)
Gross Profit9,489,600
Operating Expense-6,625,100
Operating Income4,395,0002,864,500
 
Operating Expense (+$)
Research Development3,630,300
Selling General Administrative1,464,300
Selling And Marketing Expenses0
Operating Expense6,625,1005,094,600
 
Net Interest Income (+$)
Interest Income598,100
Interest Expense-30,600
Other Finance Cost-0
Net Interest Income567,500
 
Pretax Income (+$)
Operating Income4,395,000
Net Interest Income567,500
Other Non-Operating Income Expenses0
Income Before Tax (EBT)248,5009,109,000
EBIT - interestExpense = -30,600
-535,600
-505,000
Interest Expense30,600
Earnings Before Interest and Taxes (EBIT)0279,100
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax248,500
Tax Provision-784,100
Net Income From Continuing Ops-535,600-535,600
Net Income-535,600
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net-4,714,000-567,500
 

Technical Analysis of VERTEX PHARMACEUTIC (VX1.SG)
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of VERTEX PHARMACEUTIC (VX1.SG). The general trend of VERTEX PHARMACEUTIC (VX1.SG) is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine VERTEX PHARMACEUTIC (VX1.SG)'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. VERTEX PHARMACEUTIC (VX1.SG) Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of VERTEX PHARMACEUTIC (VX1.SG).

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 385.70 < 395.10 < 412.10.

The bearish price targets are: 378.95 > 368.00 > 365.00.

Know someone who trades $VX1? Share this with them.👇

VERTEX PHARMACEUTIC (VX1.SG) Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of VERTEX PHARMACEUTIC (VX1.SG). The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

VERTEX PHARMACEUTIC (VX1.SG) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of VERTEX PHARMACEUTIC (VX1.SG). The current macd is -9.44536348.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the VERTEX PHARMACEUTIC (VX1.SG) price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for VERTEX PHARMACEUTIC (VX1.SG). This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the VERTEX PHARMACEUTIC (VX1.SG) price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
VERTEX PHARMACEUTIC (VX1.SG) Daily Moving Average Convergence/Divergence (MACD) ChartVERTEX PHARMACEUTIC (VX1.SG) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of VERTEX PHARMACEUTIC (VX1.SG). The current adx is 26.38.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell VERTEX PHARMACEUTIC (VX1.SG) shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
VERTEX PHARMACEUTIC (VX1.SG) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of VERTEX PHARMACEUTIC (VX1.SG). The current sar is 445.35.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
VERTEX PHARMACEUTIC (VX1.SG) Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of VERTEX PHARMACEUTIC (VX1.SG). The current rsi is 27.32. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
VERTEX PHARMACEUTIC (VX1.SG) Daily Relative Strength Index (RSI) ChartVERTEX PHARMACEUTIC (VX1.SG) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of VERTEX PHARMACEUTIC (VX1.SG). The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the VERTEX PHARMACEUTIC (VX1.SG) price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
VERTEX PHARMACEUTIC (VX1.SG) Daily Stochastic Oscillator ChartVERTEX PHARMACEUTIC (VX1.SG) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of VERTEX PHARMACEUTIC (VX1.SG). The current cci is -299.7092735.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
VERTEX PHARMACEUTIC (VX1.SG) Daily Commodity Channel Index (CCI) ChartVERTEX PHARMACEUTIC (VX1.SG) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of VERTEX PHARMACEUTIC (VX1.SG). The current cmo is -58.84048083.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
VERTEX PHARMACEUTIC (VX1.SG) Daily Chande Momentum Oscillator (CMO) ChartVERTEX PHARMACEUTIC (VX1.SG) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of VERTEX PHARMACEUTIC (VX1.SG). The current willr is -91.56452776.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
VERTEX PHARMACEUTIC (VX1.SG) Daily Williams %R ChartVERTEX PHARMACEUTIC (VX1.SG) Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of VERTEX PHARMACEUTIC (VX1.SG).

VERTEX PHARMACEUTIC (VX1.SG) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of VERTEX PHARMACEUTIC (VX1.SG). The current atr is 11.83.

VERTEX PHARMACEUTIC (VX1.SG) Daily Average True Range (ATR) ChartVERTEX PHARMACEUTIC (VX1.SG) Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of VERTEX PHARMACEUTIC (VX1.SG). The current obv is 1,682.

VERTEX PHARMACEUTIC (VX1.SG) Daily On-Balance Volume (OBV) ChartVERTEX PHARMACEUTIC (VX1.SG) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of VERTEX PHARMACEUTIC (VX1.SG). The current mfi is 29.46.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
VERTEX PHARMACEUTIC (VX1.SG) Daily Money Flow Index (MFI) ChartVERTEX PHARMACEUTIC (VX1.SG) Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for VERTEX PHARMACEUTIC (VX1.SG).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-17STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-12-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-14ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-01-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-01-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-01-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-31BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-02-11ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-28MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-17STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-09STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-08ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

VERTEX PHARMACEUTIC (VX1.SG) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of VERTEX PHARMACEUTIC (VX1.SG) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5027.317
Ma 20Greater thanMa 50429.545
Ma 50Greater thanMa 100445.827
Ma 100Greater thanMa 200435.286
OpenGreater thanClose383.350
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of VERTEX PHARMACEUTIC (VX1.SG) with someone you think should read this too:
  • Are you bullish or bearish on VERTEX PHARMACEUTIC (VX1.SG)? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about VERTEX PHARMACEUTIC (VX1.SG)? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about VERTEX PHARMACEUTIC (VX1.SG)

I send you an email if I find something interesting about VERTEX PHARMACEUTIC (VX1.SG).


Comments

How you think about this?

Leave a comment

Stay informed about VERTEX PHARMACEUTIC (VX1.SG).

Receive notifications about VERTEX PHARMACEUTIC (VX1.SG) in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.